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Abstract 
Background: In healthy population cohorts, resting heart rate above 90bpm is 
associated with mortality from coronary heart disease (CHD) but it is not clear whether 
associations are present at lower heart rates or whether these associations differ 
between women. 
 
Methods: Linked electronic health records from primary care, hospitalisations, 
myocardial infarction, and cause-specific mortality records in UK were used to assess 
associations between RHR and 12 fatal and non-fatal coronary, cardiac, cerebral and 
peripheral vascular CVDs and death using Cox proportional hazard models.  
 
Results: Among 233,970 patients, 29,690 fatal and non-fatal events occurred. Fully 
adjusted models showed that RHR was not associated in men or women with 
cerebrovascular events. In men a RHR 70-79bpm (29.1% of all men) vs <60bpm was 
associated with increased risk of heart failure (HR=1.65 (95% CI: 1.26-2.16)), 
unheralded coronary death (HR=1.65 (95% CI: 1.13-2.41)), total cardiovascular events 
(HR=1.22 (95% CI: 1.15-1.28)) and all-cause mortality (HR=1.39 (95% CI: 1.22-
1.58)). Women with a higher RHR level of 80-89bpm vs 60bpm had higher risk of 
total CVD events (HR=1.17 (95% CI: 1.07-1.24)) and all-cause mortality (HR=1.21 
(95% CI: 1.07-1.35)) compared to RHR <60bpm. The risk was also present at higher 
heart rates (>90) for HF and sudden cardiac death. 
 
Conclusions: A clinically recorded RHR in the general population is specifically 
associated with the incidence of certain major CVDs and death with the risk starting 
at lower RHR levels in men compared to women.  Further research is required to 
evaluate whether interventions to lower RHR are warranted to prevent disease. 
The study is registered at: clinicaltrials.gov (ID: NCT01947361) 
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Introduction 
Heart rate  is a biomarker, increasingly recorded by people monitoring their 
own health with mobile devices and phone applications and an easily 
accessible routinely collected clinical marker in general practice (1-3). In 
epidemiological studies conducted under conditions tailored for research 
purposes, resting heart rate above 90bpm was clearly associated with 
mortality from coronary heart disease (CHD)(4) and all-causes (4-8), but have 
not established thresholds (for public health education or clinical practice) 
defining a “normal” heart rate at which risk of cardiovascular events is at its 
lowest. About a third of the adult population has a resting heart rate measured 
in clinical practice of 70-79 beats per minute, yet reliable estimates of risk at 
this level are lacking.  
 
Currently, there is a lack of large scale population based studies of clinically 
recorded resting heart rate and it is not known whether such records replicate 
findings from cohorts in which heart rate is measured under research 
conditions (9). Furthermore, little is known about the specificity of the 
associations between clinical resting heart rate and the incidence of specific 
CVDs with the majority of studies  examining aggregated cardiovascular 
outcomes (4, 10) (Table S1 (in Supplement)).  It is well known that women 
have higher resting heart rates than men (7, 11), but there is a lack of 
sufficiently large studies powered to reliably detect sex differences. 
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The objectives therefore of our research were i) to determine the extent to 
which heart rate measured in clinical practice is associated with the incidence 
of 12 different cardiac, coronary, cerebrovascular and peripheral vascular 
diseases; ii) to identify potential differences in associations between women 
and men; and iii) to determine whether there is evidence of a threshold in risk 
and whether this risk extends into lower heart rate ranges. We used large 
scale, population based linked primary-hospital care electronic health records 
(EHRs) in the CALIBER (ClinicAL disease research using LInked Bespoke 
studies and EHRs) resource (12), We have previously demonstrated the 
validity of these data for a wide range of cardiovascular risk factors (age, and 
sex (13), systolic and diastolic blood pressure (14), and smoking(15)) across 
a wide range of incident CVDs (13-15).  
 
Methods 
 
Data resource  
CALIBER links patient records from four different data sources: Primary care 
(Clinical Practice Research Database (CPRD)(16), the Myocardial Ischaemia 
National Audit Project registry (MINAP)(17), Hospital Episodes Statistics 
(HES)(18), and the Office for National Statistics (ONS)(19). CPRD data were 
used to obtain heart rate measurements, demographic variables and other risk 
factors. CPRD patients are representative of the UK population in terms of 
sex, age, ethnicity (20) and overall mortality (21) and have been validated for 
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epidemiological research (22). A description of the CALIBER approach and 
phenotyping algorithms combining Read, ICD-10, drug and procedure codes 
to define risk factors and endpoints are available at 
http://www.caliberresearch.org/portal/.  
 
Study Population and heart rate 
An open cohort of 233,970 people was drawn from registrants between 
January 1997 and March 2010 with 225 primary care practices who consented 
to data linkage (Figure S1). We included people aged ≥30 years at study entry 
(‘index date’), with ≥1 year registration prior to the index date, no prior 
diagnosis of CVD and with at least one recorded heart rate measurement. 
Heart rate was prospectively recorded by general practice staff during 
consultations. Although the method of measurement is not recorded in the 
EHR, 82.6% of people with a heart rate record had a blood pressure 
measurement the same day, suggesting that a large proportion of heart rate 
measurements were obtained using an automated blood pressure device. The 
distributions of heart rate measured on the same and different dates as blood 
pressure is presented in Fig S2. Follow-up started from the date of their first 
heart rate measurement. Participants were censored on the earliest of the 
following dates: leaving the practice, last submission of data, death, or 
endpoint occurrence.  
 
Cardiovascular risk factors  
 
 
6 
Information on cardiovascular risk factors was obtained from primary care, 
as recorded during consultations in primary care. Identical to previous reports 
we defined baseline cardiovascular risk factors using the most recent 
measurement (or prescription) recorded in CPRD up to one year before or on 
the date of study entry. Socioeconomic status was derived from the ONS 
using the Index of Multiple Deprivation (IMD) 2007 (23). It was divided into 
five categories (quintiles), the 1st quintile corresponding to the least deprived 
and the 5th quintile to the most deprived groups.  
 
Incident cardiovascular diseases  
We defined 12 CVDs identical to our previous reports (13, 14) using the four 
data sources to define first occurrence of non-fatal or fatal CVDs. Additional 
composite endpoints analysed were total CVD events, CVD deaths and all-
cause mortality. Diagnoses were identified using codes from the International 
Classification of Diseases 10th Revision (ICD 10)  for the hospital data (HES) 
and mortality data (ONS), from Read Codes for primary care data and 
bespoke variables in the ACS registry (MINAP).   
 
Statistical Analysis  
We analysed heart rate in categories (<60, 60-69, 70-79, 80-89, >90bpm) and 
used<60bpm as the reference level. Additionally, to explore whether digit 
preference might affect the results, we divided it into quintiles (30-65 bpm, 
66-72 bpm, 73-79 bpm, 80-87 bpm, 88-150bpm). The association between 
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heart rate and each disease was assessed using Cox proportional hazard 
models, adjusted for baseline age (classified by sex) as the first step and then 
for established cardiovascular risk factors (age, sex, social deprivation, 
smoking, systolic blood pressure, BP lowering medication, total cholesterol, 
high-density lipoprotein, low-density lipoprotein, type 2 diabetes and body 
mass index [BMI]) and used multiple chained equations when data missing at 
random (S3). Sex specific estimates are reported due to evidence of 
interaction with sex. Models were stratified by primary care practice. Separate 
analyses excluding participants prescribed beta-blockers at baseline and 
similarly for Ca-channel blockers was carried out. Further analysis was done 
using as heart rate reference level the 70-79 bpm range (that is the level with 
the highest frequency of observations), and the heart rate of people with 
repeated heart rate measurements prior to their baseline measurement. To 
assess the shape of association between heart rate and 4 specific CVD 
endpoints in men and women, we used restricted cubic splines with 3 knots 
and the reference value of 60bpm.  Statistical analyses were performed using 
Stata statistical software (StataSe v13 and R version 3.0.3). 
 
Results 
 
Baseline characteristics  
We included 233,970 patients (58% women) with heart rate measurements 
available at baseline with mean (SD) heart rate in men 74.6bpm (14.5) and in 
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women 77.9bpm (14.0). There were 28,381 fatal and non-fatal incident CV 
events during 641,843.5 person-years of follow-up, (mean follow-up 3.26 
years).  Table 1 shows that higher resting heart rates at baseline were 
associated with female sex, social deprivation, current smoking and type 2 
diabetes and lower use of beta-blockers.  
 
Specificity of associations for different incident CVDs  
In age adjusted Cox analysis (Table S4) resting HR in men was associated 
with increased hazard of unheralded coronary death, heart failure, SCD, MI, 
peripheral arterial disease (PAD), cardiovascular mortality and all-cause 
mortality. These were stepwise relationships with no evidence of a threshold. 
The fully adjusted hazard ratios comparing a heart rate of >90bpm vs <60bpm 
were particularly strong for unheralded coronary death, SCD and heart failure 
(HF). Heart rate was not in adjusted analyses associated with the incidence of 
coronary diseases (stable angina, unstable angina, MI in women), 
cerebrovascular diseases (transient ischaemic attack, subarachnoid 
haemorrhage, ischaemic stroke, intracerebral haemorrhage), PAD or 
abdominal aortic aneurysm in men or women (Figures 1 and 2). 
  
Associations in women compared to men  
We found strong evidence in age adjusted (Table S4) and fully adjusted 
analyses that men (Figure 1) and women (Figure 2) differed in their heart 
rate-CVD associations, with associations being weaker or absent in women. 
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The fully adjusted hazard ratios comparing a heart rate of >90bpm vs <60bpm 
were particularly strong in men for unheralded coronary death (HR= 3.06 
(95% CI: 2.07-4.52)), SCD (HR= 2.71 (95% CI: 1.90-3.83)) and heart failure 
(HF) (HR=3.26 (95% CI: 2.48-4.30)) whereas these associations were 
attenuated or not present in women (Figures 1 and 2). Interactions with sex 
were significant for stable angina, heart failure, unheralded coronary death, 
PAD, TIA, CVD death, total CVD events and all-cause mortality (Fig 1, 
Table S4). For stable angina, in women only heart rate above 60bpm was 
associated with lower risks.  
 
A clinical heart rate of 70-79bpm in men (29.1% of all men) vs <60bpm 
showed an increased risk in adjusted analyses of incident heart failure 
(HR=1.65 (95% CI: 1.26-2.16)), unheralded coronary death (HR=1.65 (95% 
CI: 1.13-2.41)) and PAD (1.45 (95% CI: 1.06-1.99)), total cardiovascular 
events (HR=1.22 (95% CI: 1.15-1.28)) and all-cause mortality (HR=1.39 
(95% CI: 1.22-1.58)) (Fig 1). In women, heart rates of 70-79bpm (31% of all 
women) were not associated with any disease endpoint. Women with heart 
rates of 80-89bpm had higher total CVD events (HR=1.17 (95% CI: 1.07-
1.24)) and all-cause mortality (HR=1.21 (95% CI: 1.07-1.35)) (Fig 2).  
 
The shapes of the associations (Fig 3) further highlight these important 
differences, the hazard of unheralded coronary death and heart failure 
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increasing progressively, starting from higher heart rates in women compared 
to men.  
 
Sensitivity analyses 
Confining analyses to those men not prescribed beta-blockers  showed 
consistent associations with heart rate 70-79bpm vs <60bpm and increased 
risk of incident heart failure (HR=1.61 (95% CI: 1.04-2.48)) and unheralded 
coronary death (HR=2.87 (95% CI: 1.44-5.72)) (Figures S3 and S4). Similar 
findings were present when we excluded those prescribed calcium channel 
blockers at baseline (data not shown). Removing events occurring within the 
first year of follow up (as a means of addressing reverse causation) showed 
consistent associations in men for a heart rate of 70-79bpm for unheralded 
coronary death (HR=1.85 (95% CI: 1.18-2.89)) and heart failure (HR=1.79 
(95% CI: 1.29-2.49)) (Figures S5 and 6). Analyses using repeated heart rate 
measurements did not alter the results (Figures S7 and S8 0respectively) nor 
when we divided heart rate in quintiles to assess digit preference (Fig S9). 
 
Discussion 
 
Main findings  
This study demonstrates the specificity of the heart rate associations across a 
wide range of pathologically diverse incident CVDs in clinical practice. In 
the largest healthy population cohort studied, we show that men have stronger 
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associations with major cardiac diseases and mortality at lower heart rate 
levels than women. Our findings suggest that resting heart rate of 70-79bpm, 
seen in 29.1% of men could be associated with a CVD risk, whereas for 
women risk was largely confined to heart rates >80bpm.  
 
Associations between heart rate and stroke and PAD 
There was no association of heart rate with cerebrovascular manifestations or 
with abdominal aortic aneurysm. For PAD in men we found that risk was 
similarly increased at all heart rate levels above 60bpm, with no evidence of 
a dose response relation. In contrast to a previous study of Woodward et al.(9) 
that used a population from the Asia-Pacific region and identified strong 
associations between heart rate and specific cerebrovascular outcomes, 
although we found strong associations with HF, CVD death and all-cause 
mortality, we did not find a link between heart rate (per 10bpm increase 
starting above 65bpm) and cerebrovascular event even after replicating their 
design and correcting for dilution bias (Table S5). However, in populations 
with a different lifestyle background compared with Western populations, the 
role of HR in predicting death may be different (24). Our findings were 
consistent with a previous study of approximately 20,000 people in France 
that had a free medical examination provided by the national health care 
system. The level of HR did not predict stroke mortality in men nor in women 
regardless of the BP level (25). 
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Associations between heart rate and contractility and rhythm disorders 
In men we found a stepwise graded association between higher RHR and 
higher incident HF consistent with previous reports (26, 27). In patients with 
established heart failure, randomized controlled trials of rate reduction with 
beta-blockers and with ivabradine, have reported improvement in mortality 
and hospitalization for subsequent heart failure events (RR=0.58, P<0.001) 
regardless of sex (28). The present study further examined unheralded 
coronary death events. These are fatal MI events in which there has been no 
prior CVD events diagnosed. This definition, important in public health 
terms, has never been studied previously in large scale cohorts. 
 
We found an association between resting heart rate >90bpm and SCD, 
consistent with some previous reports (29-31) particularly prominent to 
events occurring within one year after the heart rate measurement. 
Associations of heart rate with SCD may also be consistent with experimental 
data showing diminishing ventricular fibrillation thresholds as heart rate is 
increased in stimulation studies and increasing thresholds when heart rate is 
lowered with ivabradine (32).  
 
Taken together these observations may have mechanistic implications, 
suggesting that damages of the myocardium and the electrical stability of the 
conduction system are more associated with higher heart rate and its 
autonomic drivers than to disease progression in the arterial wall, despite data 
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relating increased heart rates to a prothrombotic state (33), endothelial 
dysfunction and accelerated atherosclerosis (34).  
 
Evidence for different associations in men and women  
We found strong evidence that heart rate has different associations with CVDs 
in women and men.  We found significant sex differences for stable angina, 
HF, UCD, PAD and all-cause mortality. An increased hazard of HF that was 
greater in men and evident at heart rates >70bpm compared with women in 
whom the hazard was confined to heart rates >90bpm was also identified.  
Epidemiological studies on RHR and HF have shown weaker associations in 
women and in other smaller studies it was confined to men perhaps reflecting 
under-powering rather than a true sex difference (27).  
 
Unlike heart failure risk that showed an increase starting at lower rates in men, 
SCD appeared increased when heart rate exceeded 90bpm in both men and 
women (29-31, 35, 36). This risk was still higher when restricted to those who 
were not on beta-blockers. 
 
A “normal” heart rate of 70-79bpm, showed strong associations with UCD 
but only in men, whereas for women the risk was not present, implying a 
difference in disease pattern as was also showed by the shape of their 
associations in Figure 3. An increase in PAD risk present in men was found 
particularly for heart rates 80-89bpm. Women may not be at increased risk 
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due to haemodynamic resilience and a decrease in total peripheral resistance 
accompanying pregnancy (37). 
 
Lack of associations between heart rate and MI  
An important finding in the present study was that stepwise heart rate 
associations appeared to have some specificity to diseases of heart muscle and 
were not detected for atherothrombotic disorders, such as acute MI. In line 
with these findings, evidence from a clinical trial, the Study Assessing the 
Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients with 
Coronary Artery Disease (SIGNIFY) trial showed that heart rate reduction 
with ivabradine does not affect the risk of MI in patients with stable CAD 
(38). Mendelian randomization studies show that the genetic loci that are 
associated with heart rate are not associated with CAD or MI (39) questioning 
the causal relevance of heart rate in these diseases.   
 
Stable angina 
Despite the plausibility of an association between resting heart rate and the 
incidence of stable angina (beta blockers were developed because of the 
importance of rate control in myocardial oxygen demand) there has been a 
lack of large scale general population studies evaluating this question.  We 
found that associations with stable angina were weak in men and in women 
there was some evidence that they were inverse (i.e. highest risk in lowest 
heart rate group).   Restricting analyses to patients who underwent a Coronary 
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Artery Bypass Graft (to assess more severe angina), did not alter the results 
(data not shown).  
 
Clinical implications  
Our findings have three clinical implications. First they can be used to help 
establish normal values for men and women. Approximately 63% of men 
have heart rates >70bpm and are at risk of major CV events and death, 
whereas 43% of women that have heart rates >80bpm are at increased risk of 
total CVD events and all-cause mortality compared to heart rates <60bpm. 
These findings suggest that commonly considered as “normal” heart rate 
values particularly in men, cannot be considered harmless. Second, given the 
existence of behavioural (e.g. exercise) and pharmacological interventions 
which lower heart rate, our findings help specify the need for, and design of, 
endpoint trials that aim at lowering heart rate, as well as the revision of 
clinical guidelines in primary prevention for re-classification of HR as a 
greater risk factor for specific major outcomes such as heart failure. We found 
that men with RHR 70-79bpm that have not been prescribed beta-blockers 
medication were at increased risk of unheralded death and heart failure (Fig 
S4). Third, our findings suggest evaluation of the contribution that heart rate 
makes to risk prediction, taking account of specific outcomes of interest (e.g. 
HF) and recognizing that existing tools such as SCORE and Framingham 
include disorders with weak or absent associations with heart rate in their 
aggregate CVD endpoints (40).  
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Strengths and limitations  
The main strength of this study lies in a population based large scale cohort 
of 233,970 men and women with clinical resolution of 12 different CVD 
presentations. It is the first study to use clinical heart rate measurements 
recorded using EHRs and therefore has intrinsic clinical relevance.  
 
Our study has important limitations. Patients with a resting heart rate recorded 
within CALIBER were older than those without a heart rate record (see Table 
S3). However, the mean heart rate values that we observed of 74bpm in men 
and 77bpm in women were similar to those reported in general population 
samples based on resting heart rate measured under research conditions.(11) 
This supports the population representativeness of CALIBER heart rate 
recordings. To account for potential reverse causality effects, we excluded 
cardiovascular events that occurred within the first year of follow-up; with 
the exception of SCD associations were if anything stronger (Figures S5, S6). 
Additionally, electronic health records lack measures of physical activity or 
physical fitness, which may influence RHR levels.  
 
Conclusions  
Resting heart rate of 70-79bpm in men in the general population was 
associated with a higher risk of specific major CVDs and death, while in 
women, risks were mainly apparent at heart rates above 90bpm. Future 
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research should replicate our findings in other real world cohorts, while trials 
of interventions to lower heart rate for primary prevention are required.  
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